Related Experiment Video
Updated: Jun 27, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
Olga-Maria Iova1,2, Gheorghe-Eduard Marin1, Vlad Răzniceanu1
1Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hațieganu", 400023 Cluj-Napoca, Romania.
Abstract:
Anaplastic thyroid carcinoma (ATC) represents the most aggressive thyroid malignancy, characterized by rapid progression, therapeutic resistance, and poor prognosis. Conventional treatments remain largely ineffective, highlighting the need for novel therapies. Metabolic reprogramming, particularly the Warburg effect (WE), has emerged as a promising area of investigation. This review synthesizes current evidence on the role of WE in ATC and PDTC, integrating data from molecular profiling, preclinical studies, and emerging therapeutic strategies. Oncogenic alterations frequently observed in ATC, including mutations in BRAF, RAS, TP53, and activation of PI3K/AKT/mTOR and HIF-1α signaling, converge to promote glycolytic reprogramming. This metabolic shift supports tumor proliferation, immune evasion, and metastasis through increased glucose uptake, lactate production, and microenvironmental remodeling. Key metabolic nodes, including glucose transporters, hexokinase, and monocarboxylate transporters, are regarded as promising targets. Preclinical studies suggest that pharmacological inhibition of these pathways reduces tumor growth, enhances radiosensitivity, and improves response to targeted therapies. Future efforts should focus on combination therapies, biomarker-driven patient stratification, and the development of targeted delivery systems to overcome toxicity and resistance. A deeper understanding of tumor metabolic heterogeneity will be essential for translating these approaches into clinical practice.
Insights
Anaplastic thyroid carcinoma (ATC) exhibits aggressive behavior and resistance to conventional treatments. Targeting the Warburg effect (WE), a metabolic reprogramming, shows promise for novel therapies by inhibiting key metabolic pathways to reduce tumor growth and improve treatment response.
Area of Science:
- Oncology
- Cancer Metabolism
- Molecular Biology
Background:
- Anaplastic thyroid carcinoma (ATC) is a highly aggressive thyroid cancer with poor prognosis.
- Current treatments for ATC are largely ineffective, necessitating novel therapeutic strategies.
- Metabolic reprogramming, specifically the Warburg effect (WE), is increasingly recognized in cancer development.
Purpose of the Study:
- To review the role of the Warburg effect (WE) in anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC).
- To integrate molecular profiling, preclinical data, and therapeutic strategies targeting WE in thyroid cancer.
- To highlight key metabolic targets and future directions for treating aggressive thyroid malignancies.
Main Methods:
- Literature review synthesizing evidence on WE in ATC and PDTC.
- Analysis of molecular profiling data identifying oncogenic alterations driving metabolic reprogramming.
- Examination of preclinical studies on pharmacological inhibition of metabolic pathways.
Main Results:
- Oncogenic alterations (BRAF, RAS, TP53, PI3K/AKT/mTOR, HIF-1α) promote glycolytic reprogramming in ATC.
- WE supports tumor proliferation, immune evasion, and metastasis via increased glucose uptake and lactate production.
- Inhibition of key metabolic nodes (e.g., glucose transporters, hexokinase) shows potential in preclinical models.
Conclusions:
- Targeting WE offers a promising therapeutic avenue for ATC and PDTC.
- Pharmacological inhibition of metabolic pathways can reduce tumor growth and enhance sensitivity to other treatments.
- Future research should focus on combination therapies, biomarkers, and overcoming resistance for clinical translation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...